PMS-SITAGLIPTIN-METFORMIN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

METFORMIN HYDROCHLORIDE; SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE)

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

A10BD07

INN (আন্তর্জাতিক নাম):

METFORMIN AND SITAGLIPTIN

ডোজ:

1000MG; 50MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

METFORMIN HYDROCHLORIDE 1000MG; SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0252656003; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2023-01-05

পণ্য বৈশিষ্ট্য

_pms-SITAGLIPTIN-METFORMIN (sitagliptin and metformin hydrochloride) _
_Page 1 of 63_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-SITAGLIPTIN-METFORMIN
Sitagliptin and Metformin Hydrochloride Tablets
Sitagliptin (as sitagliptin phosphate monohydrate) and metformin
hydrochloride
Tablets, 50 mg/500 mg and 50 mg/1000 mg, Oral
Combinations of oral blood glucose lowering drugs
PHARMASCIENCE INC.
Date of Initial Authorization:
6111 Royalmount Ave., Suite 100
November 7, 2022
Montréal, Canada
H4P 2T4
Submission Control Number: 250448
_pms-SITAGLIPTIN-METFORMIN (sitagliptin and metformin hydrochloride) _
_Page 2 of 63_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.....................................................................
5
4
DOSAGE AND ADMINISTRATION
........................................................................................
5
4.1
Dosing Considerations
..............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 6
4.4
Administration..............................................